Next, we boosted immunizations with IL-15:IL-15Rα-B16F10-OVA with the same doses 2 weeks after the priming injection to analyze whether the boosting immunization would protect against future exposure to live cancer cell injection in mice (Figure 3A). The gene discussed is IL15; the disease is cancer.